CompletedPhase 4Results posted

Effect of DPP4 Inhibition on Growth Hormone Secretion

The Effect of Dipeptidyl Peptidase IV Inhibition on Growth Hormone-Mediated Vasodilation

Lead sponsor

Vanderbilt University

Asset

Avexitide

Listed sites

Recruiting sites

Actual enrollment

Study population

Obesity / overweight

Eligibility highlights

•BMI ≤25

Primary endpoint

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01701973

Org study ID120078

Secondary ID1K23HL119602

Timeline

Milestones

Study first posted2012-10-05estimated

Last update posted2018-05-29actual

Results first posted2018-05-29actual

Study start2013-01 (month precision)

Primary completion2017-05actual (month precision)

Study completion2017-05actual (month precision)

Assets

Investigational agents

Avexitide

Who this study enrolls

Obesity / overweight

Who can enroll

Minimum age18 Years

Maximum age40 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•Age 18 to 40 years inclusive

•BMI ≤ 25 kg/m2

•For female subjects:

Status-post surgical sterilization, or If of child-bearing potential, utilization of a barrier method of birth control following negative serum pregnancy test at screening visit and on every study day

Exclusion criteria

•Smoking

•Type 1 or Type 2 Diabetes Mellitus, as defined by a fasting glucose of 126 mg/dL or greater at the time of screening visit or the use of anti-diabetic medication

•Hypertension, as defined by an untreated seated systolic blood pressure (SBP) greater than 140 mmHg and/or an untreated diastolic blood pressure (DBP) greater than 90 mmHg at the time of screening visit or the use of anti-hypertensive medication

•History of reported or recorded hypoglycemia (plasma glucose < 70 mg/dL)

•Pregnancy and/or Breast-Feeding

•Use of any medication other than multivitamin, including use of transdermal as well as oral hormone replacement therapy or use of oral contraceptive therapy

•Anemia defined as hematocrit <35% at screening visit

•Cardiovascular or cerebrovascular disease, including history of myocardial infarction, history of congestive heart failure, history of stroke

•Pulmonary Hypertension

•Abnormal thyroid hormone levels (TSH) at the time of screening visit

•Abnormal serum insulin like growth factor-1 (IGF-1) at the time of screening visit

•Impaired renal function, defined as estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m^2

•Impaired hepatic function (alanine or aspartate transaminase > 2 X upper limit of normal range)

•Treatment with an investigational drug in the 1 month preceding the study

Endpoints (0)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

No endpoints recorded for this trial.

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.